0.131
2.17%
-0.0029
NLS Pharmaceutics Ltd stock is currently priced at $0.131, with a 24-hour trading volume of 36,759.
It has seen a -2.17% decreased in the last 24 hours and a -25.53% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.1342 pivot point. If it approaches the $0.1307 support level, significant changes may occur.
Previous Close:
$0.1339
Open:
$0.1341
24h Volume:
36,759
Market Cap:
$5.88M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-0.156
EPS:
-0.84
Net Cash Flow:
$-13.51M
1W Performance:
-1.06%
1M Performance:
-25.53%
6M Performance:
-80.16%
1Y Performance:
-90.58%
NLS Pharmaceutics Ltd Stock (NLSP) Company Profile
Name
NLS Pharmaceutics Ltd
Sector
Industry
Phone
41 44 512 21 50
Address
The Circle 6, Zurich
NLS Pharmaceutics Ltd Stock (NLSP) Latest News
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Hawaiian Airlines Shares Are Trading Higher By Over 180%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
NLS Pharmaceutics Ltd Stock (NLSP) Financials Data
NLS Pharmaceutics Ltd (NLSP) Net Income 2024
NLSP net income (TTM) was -$15.47 million for the quarter ending June 30, 2023, a -148.17% decrease year-over-year.
NLS Pharmaceutics Ltd (NLSP) Cash Flow 2024
NLSP recorded a free cash flow (TTM) of -$13.51 million for the quarter ending June 30, 2023, a -36.06% decrease year-over-year.
NLS Pharmaceutics Ltd (NLSP) Earnings per Share 2024
NLSP earnings per share (TTM) was -$0.50 for the quarter ending June 30, 2023, a +12.86% growth year-over-year.
About NLS Pharmaceutics Ltd
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Cap:
|
Volume (24h):